A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes

• Status: Completed
• Trial end date: 2013-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Glimepiride; Glucagon-Like Peptide 1; Metformin; Pioglitazone; rGLP-1 protein

Criteria

Inclusion Criteria:

• type 2 diabetes

• BMI 20-45kg/m2 inclusive

Exclusion Criteria:

• females who are pregnant, lactating, or less than 6 weeks post-partum

• current symptomatic heart failure (NYHA Class II-IV)